News
PTN
1.780
+3.49%
0.060
Weekly Report: what happened at PTN last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at PTN last week (0408-0412)?
Weekly Report · 04/15 10:29
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Insider transactions for penny stocks indicate confidence or concern around the company's prospects. Augusta Gold Corp. And Tecogen Inc. Are two companies with recent notable insider transactions. The Dow Jones index closed slightly lower on Thursday. Palatin Technologies, Inc. And Augusta Gold Corporation are among the recent penny stocks with notable insider trades.
Benzinga · 04/12 12:36
BUZZ-U.S. STOCKS ON THE MOVE-JPMorgan, Ameresco, Copper miners
Wall Street's main stock indexes advanced in choppy trading on Monday. The Dow Jones Industrial Average was up 0.10% at 38,941.91. The top three S&P 500 percentage gainers were Tesla, GE and Ameresco. Treasury yields retreated from session highs as investors awaited the Fed's rate outlook.
Reuters · 04/08 16:11
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
TipRanks · 04/08 15:05
Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643
Palatin Technologies shares were up 27% to $2.24. The company said it saw positive topline results for its Phase 3 pivotal clinical trial. The stock hit its 52-week high of $5.65 on Jan. 29. Palatin said the study demonstrated positive results for dry eye disease treatment.
Dow Jones · 04/08 14:46
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
Palatin Technologies Inc. Announced topline results for its Phase 3 dry eye disease trial. The company says PL9643 has a superior safety and tolerability profile. Dry eye disease is one of the most common ocular disorders in the U.S. The dry eye market is estimated to be $6.11 billion.
Benzinga · 04/08 14:02
Palatin stock jumps 16% on positive Phase 3 data for eye drug
Palatin stock jumps 16% on positive Phase 3 data for eye drug for dry eye disease. Palatin Technologies reported positive data for its drug candidate PL9643 in the treatment of dry eye diseases. The company is in talks with potential partners for the product, Palatin says.
Seeking Alpha · 04/08 13:49
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack. Auddia AUUD +123% on bagging a U.S. Patent for the core AI technology it uses in its radio app. Bitcoin again surpassed the $72,000 level.
Seeking Alpha · 04/08 13:10
PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE (DED) CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY (ASCRS) 2024
Reuters · 04/08 11:30
Weekly Report: what happened at PTN last week (0401-0405)?
Weekly Report · 04/08 10:33
Weekly Report: what happened at PTN last week (0325-0329)?
Weekly Report · 04/01 10:32
Weekly Report: what happened at PTN last week (0318-0322)?
Weekly Report · 03/25 10:34
Weekly Report: what happened at PTN last week (0311-0315)?
Weekly Report · 03/18 10:33
Palatin files to sell 1.92M shares of common stock for holders
Palatin files to sell 1.92M shares of common stock for holders Mar. 14, 2024 4:30 PM ETPalatin Technologies, Inc. (PTN) Stock Palatin Technologies filed a prospectus related to the proposed resale of 1. 92 million common shares by the selling stockholders.
Seeking Alpha · 03/14 20:30
Weekly Report: what happened at PTN last week (0304-0308)?
Weekly Report · 03/11 10:31
Weekly Report: what happened at PTN last week (0226-0301)?
Weekly Report · 03/04 10:33
Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects
TipRanks · 02/29 12:56
Health Care Sector Update for 02/28/2024: VANI, PTN, UNH, LFST, NVO
NASDAQ · 02/28 21:01
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ:BMBL) fell sharply after the company reported weak quarterly results. Vivani Medical, Inc. Shares jumped 289% to $3.93 during Wednesday's mid-day session. Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate.
Benzinga · 02/28 19:02
More
Webull provides a variety of real-time PTN stock news. You can receive the latest news about Palatin Tech through multiple platforms. This information may help you make smarter investment decisions.
About PTN
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.